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The rapid progress in advanced imaging technologies has expanded our toolbox
for monitoring a variety of biological aspects in living subjects including human.
In vivo radiological imaging using small chemical tracers, such as with positron
emission tomography, represents an especially vital breakthrough in the efforts to
improve our understanding of the complicated cascade of neurodegenerative disorders
including Alzheimer’s disease (AD), and it has provided the most reliable visible
biomarkers for enabling clinical diagnosis. At the same time, in combination with
genetically modified animal model systems, the most recent innovation of fluorescence
imaging is helping establish diverse applications in basic neuroscience research, from
single-molecule analysis to animal behavior manipulation, suggesting the potential utility
of fluorescence technology for dissecting the detailed molecular-based consequence
of AD pathophysiology. In this review, our primary focus is on a current update of PET
radiotracers and fluorescence indicators beneficial for understanding the AD cascade,
and discussion of the utility and pitfalls of those imaging modalities for future translational
research applications. Wewill also highlight current cutting-edge genetic approaches and
discuss how to integrate individual technologies for further potential innovations.
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INTRODUCTION
Progressive neuronal loss and dysfunction in specific brain circuits are common neurological
features of neurodegenerative disorders. The fundamental mechanism of neurodegenerative onset
is still largely unknown, but accumulating evidence has indicated that deposition of filamentous
and/or soluble oligomeric aggregates of specific proteins with significant neurotoxicity generally
serves as the initial trigger for the sequential cascade of disease-related pathophysiology. In brain
of Alzheimer’s disease (AD) patients, senile plaques (SPs), and neurofibrillary tangles (NFTs)
have been defined as two major pathological hallmarks, suggesting that the formation process
of the resulting abnormal lesions is tightly linked to the pathogenic mechanism of AD. SPs are
extracellular deposits composed of hydrophobic 38–49 amino acid peptides termed amyloid β (Aβ)
and, since the discovery of the in vitro neuronal toxicity of aggregated Aβ species, numerous studies
have indicated that brain accumulation of Aβ aggregates is a major causative risk factor for AD
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pathogenesis (Selkoe, 1991, 2001; Hardy and Selkoe, 2002). This
“amyloid cascade hypothesis” is also strongly supported by the
fact that Aβ metabolism is genetically linked to the familial
AD causative genes β-amyloid precursor protein (APP) and
Presenilins (PSs), adding major impetus to diverse therapeutic
attempts to attenuate brain Aβ abnormality over the last
two decades. However, in spite of these various advances in
knowledge, no therapeutic approaches targeting Aβ have as yet
successfully survived a Phase III trial (Huang and Mucke, 2012).
This situation has now brought us to a turning point, as we
need to re-evaluate our understanding of the consequences of AD
pathophysiology and to carefully consider the direction of future
therapeutic approaches so as to finally gain advantage over these
complicated neurological disorders.
NFTs are composed of intra-neuronal and glial inclusions
of hyperphosphorylated microtubule-associated protein Tau
(MAPT), and they are widely observed in diverse tauopathies
including progressive supranuclear palsy (PSP) and corticobasal
degeneration (CBD), suggesting their importance for general
neurodegenerative abnormalities (reviewed in Lee et al., 2001).
In the pathological course of AD, NFTs begin to appear in
the entorhinal cortex and then spatially spread through a wide
range of brain areas including the hippocampus, limbic system,
and neocortex (Braak and Braak, 1991; Braak et al., 2011).
The severity of NFT lesions is well-correlated with synaptic
dystrophy and neuronal loss, followed by brain atrophy, and
test results of cognitive and memory impairment also revealed
correlation with brain accumulation of tau (Arriagada et al.,
1992). Importantly, pathological mutations in the genetic locus
of Tau gene have been identified in the family of frontotemporal
dementia with Parkinsonism linked to MAPT on chromosome-
17 (FTDP-17-MAPT) (Hutton et al., 1998; Poorkaj et al.,
1998; Spillantini et al., 1998). Furthermore, recent studies have
demonstrated that transgenic mouse models overexpressing
human Tau transgene harboring pathogenic FTDP-17-MAPT
mutations exhibit robust NFTs formation followed by neuronal
loss and memory impairment (reviewed in Sahara et al.,
2011). These findings suggest that abnormal aggregation and/or
physiological malfunction of Tau protein has more potential
significance for neurodegeneration, and indicate that the severity
of tau pathology is also a potent biomarker for the early clinical
diagnosis of AD.
As proposed in Braak’s model, the pathological severities of
SPs and NFTs in post-mortem AD brains can be categorized
into progressive stages (stages A-C for SPs and I-VI for
NFTs), providing fundamental criteria for a definitive diagnosis
of AD (Braak and Braak, 1991, 1997). Hopeful attempts by
AD researchers to establish visible biomarkers for tracing the
real time course of Aβ and tau lesions in brain of living
patients have followed a long, sometimes frustrating journey,
as so far, histological findings at autopsy have usually suffered
from technical limitations during the post-mortem procedure.
In this regard, an in vivo imaging approach is particularly
important for assessing the consequence of clinical symptoms
and spatial dynamics of pathological lesions simultaneously. For
this purpose, non-invasive neuroimaging techniques represented
by positron emission tomography (PET) andmagnetic resonance
imaging (MRI) have a major significance, as they allow us to
monitor both functional and structural circumstances in brain
of AD patients (Mori et al., 2012; Jack and Holtzman, 2013).
Aβ PET radiotracers have been developed and approved for
clinical use, and they have added in shedding more light on the
process of the early detection of AD (Yang et al., 2012). More
recently, several laboratories including our group demonstrated
the potential utility of tau-specific PET radiotracers to validate
the spatiotemporal kinetics of the pathological stage of NFTs
(reviewed in Ariza et al., 2015; Villemagne et al., 2015). These
consistent advances of radiological imaging technologies are
really just a beginning stage, and further accumulations of new
insights and important knowledge for constructing biomedical
databases will be required for future translational research. It
is important to realize that there is still a lot of room to
manipulate and improve the capability of PET radiotracers
in terms of binding specificity and chemical properties that
can critically improve the diagnostic interpretation of PET
neuroimaging. To visualize the brain status of AD more
precisely, complimentary imaging approaches will be essential
for assessing the detailed kinetics and fast dynamics of target
molecules. Fluorescence-based imaging has great potential as
a key technology to satisfy this aim. Although the utility
of fluorescence is still restricted to animal models at this
time, the major advantages of the fluorescence system are a
variety of applications based on a wide range of probe design
strategies including molecular genetics for dissecting the detailed
molecular pathophysiology of neurodegenerative diseases. In
this review, we will specifically introduce current imaging
multimodalities beneficial for understanding the AD cascade and
discuss how to integrate the respective modalities to the view
of providing significant advances toward future translational
research.
PET IMAGING FOR DIAGNOSIS OF
ALZHEIMER’S DISEASE
General Usage for Brain PET Imaging
Radiological techniques supply a variety of applications for
in vivo brain imaging, becoming a most effective approach
in terms of the clinical diagnosis of neurological disorders.
PET technology is especially adept at monitoring the behavior
of neuronal molecules in living subjects including rodent,
monkey, and human. Although the spatial resolution obtained
by MRI, which is superior for morphometric analysis, is much
higher than that of PET imaging, the performance of PET
is greatest in the quantification of the kinetics of neuronal
receptor molecules and chemical probe interaction in intact
brain. In principle, chemical probes are labeled by positron
emitting radionuclides such as 11C and 18F, and PET scan
identifies the spatial location of these probes as radiotracers
with high detection sensitivity and superior quantitative dynamic
range (Piel et al., 2014). Therefore, we can directly obtain a
densitometric 3D map of the accumulation level of radiotracers
binding to targets. A number of small chemical compounds with
high affinity to target molecules can be screened as potential
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candidates of PET radiotracers without disrupting their parental
structure and physicochemical properties. Only a small amount
of radiation emitted from the tracer can be enough to allow
detection, without any diffusion, and relatively fast decay of
the radioisotope (t1/2 = ∼20min for
11C, ∼110min for 18F)
minimizes the radiation risk for patients (Piel et al., 2014).
Furthermore, PET scan also provides important information
about the detailed disposition and tissue circulation of the
radiotracers themselves in brain, facilitating the design and
synthesis of effective chemical derivatives that can successfully
pass through the blood brain barrier (BBB) and penetrate brain
tissue without obvious neurotoxicity (Piel et al., 2014). This basic
feature of PET imaging makes this technology ideal for clinical
use, and it also provides various potential utilities for scientific
research.
PET Tracers for Detecting Aβ and Tau
Pathologies
Since the initial discovery of the β-sheet enriched common
structure in the aggregates of Aβ and tau, various β-sheet
binding dyes such as congo-red and thioflavin have been
isolated as candidate compounds for PET imaging, and their
use for visualizing SPs and NFTs in animal models and
human subjects has been attempted. Representative and currently
available Aβ and tau PET tracers are listed in Table 1. The
earliest PET studies identified the capability of [18F]FDDNP, a
fluorine-modified derivative of the lipophilic compound DDNP,
as Aβ PET tracer (Barrio et al., 1999; Small et al., 2006).
However, this tracer has not become widely used for in vivo
imaging because it demonstrates a relatively low signal-to-noise
ratio, and it also recognizes NFTs, which makes interpretation
difficult (Shoghi-Jadid et al., 2002; Thompson et al., 2009;
Smid et al., 2013). A superior Aβ-specific PET tracer termed
[11C]Pittsburgh Compound-B ([11C]PiB) was screened as a
derivative of thioflavin T, and it is now the most widely
characterized radio ligand with improved sensitivity and high
specificity against Aβ aggregate (Klunk et al., 2004). A 18F-labeled
analog of PiB, termed [18F]3′-FPiB (Flutemetamol; Vizamyl, GE
Healthcare), was developed for diagnostic application and was
approved by the US Food and Drug Administration (Yang et al.,
2012). In parallel, other Aβ PET tracers, [18F]AV-45 (florbetapir;
Amyvid, Eli Lily) and [18F]AV-1 (florbetaben; Neuraceq, Piramal
Imaging), have also been independently engineered from diaryl
alkenes and are currently available for clinical diagnosis (Herholz
and Ebmeier, 2011; Vallabhajosula, 2011). For the purpose of
standardizing the difference of these Aβ PET tracers, several
groups have investigated direct comparison of PET imaging
data obtained by sequential scanning using several tracers in
the same cohort (Vandenberghe et al., 2010; Wolk et al., 2012;
Landau et al., 2013, 2014). As for the cortical retention ratio
of [11C]PiB, both [18F]3′-FPiB and [18F]AV-45 demonstrate
a highly significant ability to discriminate between control
subjects and AD patients, with a high linear correlation to the
data obtained by [11C]PiB. However, it has been pointed that
the retention level in white matter varies among the tracers,
which makes it more challenging to precisely measure the
cortical retention ratio to the reference brain region such as
the brain stem, which contains a large amount of white matter
(Landau et al., 2014). Hence, it would still be a worthwhile
investment to improve and characterize the capability of Aβ
PET tracers (Kudo et al., 2007; Yousefi et al., 2011; Cselenyi
et al., 2012). The development race of Tau PET tracers is just
heating up (reviewed in Ariza et al., 2015; Villemagne et al.,
2015). Three lines of chemical probes have been independently
screened and characterized for their potential clinical utility
(Table 1). [18F]THK523 was originally engineered as a derivative
of quinoline, and it demonstrates high affinity and selectivity for
tau aggregates in in vitro assay (Fodero-Tavoletti et al., 2011).
Although human PET imaging using [18F]THK523 indicated its
specificity not for Aβ but for NFTs, a relatively high background
of this radiotracer in white matter was initially anticipated for
its further clinical use (Fodero-Tavoletti et al., 2011; Harada
et al., 2013). Improved novel radiotracers labeled [18F]THK5105,
TABLE 1 | Reference list for Aβ and Tau PET radiotracers.
Target Radiotracer for PET imaging
of SPs or NFTs
Approval for clinical use References
Aβ/SPs [18F]FDDNP Barrio et al., 1999; Shoghi-Jadid et al., 2002; Small et al., 2006;
Thompson et al., 2009; Smid et al., 2013
Aβ/SPs [11C]PiB Klunk et al., 2004
Aβ/SPs [18F]3′-FPiB Flutemetamol; Vizamyl, GE healthcare Yang et al., 2012
Aβ/SPs [18F]AV-1 Florbetaben; Neuraceq, Piramal imaging Rowe et al., 2008
Aβ/SPs [18F]AV-45 Florbetapir; Amyvid, Eli Lily Choi et al., 2009
Tau/NFTs [18F]THK523 Fodero-Tavoletti et al., 2011; Harada et al., 2013
Tau/NFTs [18F]THK5105 Okamura et al., 2014
Tau/NFTs [18F]THK5117 Okamura et al., 2014
Tau/NFTs [18F]THK5351 Villemagne et al., 2014
Tau/NFTs [18F]T807 Xia et al., 2013
Tau/NFTs [18F]T808 Zhang et al., 2012
Tau/NFTs [11C]PBB3 Maruyama et al., 2013
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[18F]THK5117 and [18F]THK5351, 2-arylquinoline derivatives,
were recently engineered by the same group and demonstrated
superior affinity and specificity in in vitro assays, making these
tracers promising candidates for tau PET imaging (Okamura
et al., 2014; Tago et al., 2014; Villemagne et al., 2014). [18F]T807
and [18F]T808, also screened as benzimidazole pyrimidine
derivatives, demonstrated specific selectivity to tau aggregates
with nano-molar affinity (Zhang et al., 2012; Xia et al., 2013).
Human PET studies using these radiotracers revealed significant
association between clinical severity and their cortical retention,
and this observation was also followed by a good correlation
with post-mortem pathological NFT lesions (Chien et al., 2013).
[11C]PBB3 was developed as a phenyl/pyridinyl-butadienyl-
benzothiazoles/benzothiazolium (PBB) derivative that possesses
superior affinity and specificity for NFTs, much higher than
for SPs, by radioautography using brain sections from both
rodent models and AD patients (Maruyama et al., 2013).
[11C]PBB3 PET analysis of AD patients and non-AD tauopathies
revealed that the severity of tau accumulation correlates well
with clinical scores and follows the pathological staging model
proposed by Braak. Because of it being a relatively new topic,
as well as the highly competitive nature of this research
field, a side-by-side direct comparison of the capability of the
respective tau PET tracers in the same individuals has not
yet been achieved. However, recent studies based on in vitro
binding assays indicate that those various tracers demonstrate
preferential binding capability to distinctive tau pathologies
observed in AD and non-AD, suggesting each tracer potentially
recognizes the different structural status of tau aggregates
(Maruyama et al., 2013; Marquie et al., 2015). Overall, current
tau PET imaging is promising, and detailed characterization and
improvement of independent radiotracers will provide better
clinical insight and shed greater light on the detection of AD
progression.
Non-Amyloid PET Imaging for Detecting
Disease Progression
In addition to Aβ and Tau PET imaging, various disease-
associated pathophysiologies such as aberration of energy
metabolism, glial inflammation, dysfunction of calcium
homeostasis, and imbalanced neuronal activity can also be
targeted as potential biomarkers of AD progression. The benefits
of characterizing these additional biological parameters for
AD diagnosis are the following: (i) accumulating a repertory
of biomarkers will eventually contribute to establishing a PET
biomarker database that will allow us to conduct more precise
diagnoses and case-by-case categorizations with unbiased
criteria by the combinations of several parameters; (ii) the
signal-to-noise ratio of current amyloid PET imaging is still
being developed and is not yet sufficient to detect early stages of
pathological lesions; (iii) some of the biomarkers can be useful for
the diagnosis of other neurodegenerative disorders as common
pathophysiological abnormalities. [18F]fluordeoxy glucose
([18F]FDG) PET scan has been conducted to identify glucose
hypometabolism in AD patients, and it is generally selected as
the initial choice for the clinical diagnosis of AD (McGeer et al.,
1986; Mosconi, 2005). However, the difficulty in identifying a
specific and precise time window of the AD status has been
a matter of debate, as [18F]FDG hypometabolism reflects
various mixture effects including less neuronal excitability
and neuronal loss, which are widely observed in various
neurodegenerative disorders (Jack and Holtzman, 2013). Brain
inflammatory response with reactive gliosis is the other potential
target for staging AD progression (Heppner et al., 2015). A
considerable amount of evidence has indicated that activated
reactive astrocytes contribute to clearing SPs in the early stage
of AD. Since the inflammation is massively amplified by the
paracrine neuroprotective response, it would be one of the key
candidates as an early-stage biomarker that can detect subtle
changes indicating pathological abnormality. In fact, using a tau
transgenic mouse model, it was demonstrated that microglial
activation proceeds to NFTs formation (Yoshiyama et al.,
2007), suggesting its potential utility as a much earlier-stage
diagnostic biomarker. This evidence supports the concept of
the potential utility of several inflammation-related molecules
for early clinical diagnosis. On the other hand, it has been
debated whether inflammatory response represents both
aspects of neuroprotective and neurodegenerative signals
(Higuchi et al., 2010; Heneka et al., 2015; Heppner et al.,
2015). Particularly, there is evidence that prolonged microglial
activation accelerates the neurodegenerative process (Maeda
et al., 2007; Ji et al., 2008), suggesting a potential difficulty for
interpreting inflammatory parameters as early-stage biomarkers.
In any case, it should be feasible to target a molecule that can
segregate astrocytic and microglial activations. Based on this
concept, TSPO (Translocator Protein 18 kDa, also known as
Peripheral Benzodiazepine Receptor; PBR) has been targeted for
imaging nueroinflammation (reviewed in Jacobs et al., 2012).
Since increased TSPO expression in activated microglia has been
associated with a number of neurological diseases (reviewed
in Venneti et al., 2006), several PET tracers for TSPO (e.g.,;
[11C](R)-PK11195, [11C]PBR28, [11C]DAA1106, [11C]AC5216,
and [18F]DPA-714) have been studied to visualize the microglial
activation in animal models and AD patients (Jacobs et al.,
2012; Mori et al., 2012; Golla et al., 2015). However, there are
several limitations of current TSPO ligands such as selectivity
to microglia and different affinity in polymorphisms (reviewed
in Venneti et al., 2013; Turkheimer et al., 2015). Regardless,
imaging neuroinflammation will offer one of diagnostic tools for
neurological diseases.
Pitfalls of PET Imaging
PET imaging is an extremely powerful tool for the purpose of
non-invasive clinical diagnosis. However, it is still not easy to
install these imaging systems into a single laboratory; it would
be a costly and space-consuming challenge to establish a special
radiation control facility requiring a high level of expertise for
the maintenance and manipulation of radioactive molecules. In
addition, there are also technical limitations in regard to spatial
and temporal resolution, and there is not yet a suitable approach
for evaluating binding specificity and molecular dynamics of the
tracer, pivotal criteria for reliable imaging interpretation. For
instance, despite the development of newly screened radiotracer
candidates based on considerable effort and time for synthesis
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and radiolabeling, in vitro and ex vivo binding assays such as
autoradiography under lowmagnification are recognized as so far
being the sole method for verifying the capability of the tracer. An
additional weakness of PET technique is the inability to obtain
new biological insight into the structural and/or environmental
status of target molecules, meaning that the solid radiation
signal we monitor during PET scans completely lacks that kind
of molecular-based information. Therefore, an ideal approach
would be to evaluate the biological validity and capability of
the tracer by complementary technologies side-by-side, and this
would comprehensively enhance the developmental productivity
by mutual complementary and synergistic effect of different
technologies. In the next section, we will discuss the utility of
fluorescence imaging in the effort to lessen the gap in PET
imaging.
FLUORESCENCE IMAGING TO DISSECT
MOLECULAR PATHOPHYSIOLOGY
Utility of Fluorescence for In vivo Brain
Imaging
During the rapid evolution of optical microscope technologies
over the last several decades, fluorescence imaging has become a
powerful tool for current modern neuroscience (Giepmans et al.,
2006; Wilt et al., 2009). A variety of microscope systems with
combinations of many available fluorescence probes supply a
wide range of applications including single molecular analysis,
live cell imaging, and conventional histological analysis in animal
brain. In particular, the recent availability of the multi-photon
excitation technique has broken down the limitation of optical
scattering in thick tissues and expanded the utility of fluorescence
for in vivo brain imaging in animal models (reviewed in Svoboda
and Yasuda, 2006). In this system, only target fluorophores in
a restricted volume can be excited by simultaneous photon
absorption using a long-wavelength pulse laser, allowing us to
illuminate molecular dynamics up to a depth of ∼1mm. To
conduct a long period of efficient excitation and detection (at
least 1 month), setting of a chronic cranial window onto the bone
of the skull is generally used (Tomita et al., 2005). Furthermore,
current progress of fluorescence-based microendoscopy using
optical fibers has enabled us to conduct cellular level imaging
within the deep areas of brain tissue such as hippocampus and
striatum in freely moving animals (reviewed inMehta et al., 2004;
Oh et al., 2013). In spite of mechanical inflexibility and physical
invasiveness caused by surgical insertion of submillimeter-
diameter fiber optic devices, it offers potential applications
for longitudinal studies of disease progression (Barretto et al.,
2011). At this stage, these approaches are specifically limited
to usage in rodent models and is technically still far removed
from any availability for human diagnosis. However, the
combinatorial use of the AD mouse model with multi-color
fluorescence probes should represent a beneficial approach for
the monitoring of the progressive course of the AD cascade
simultaneously, relying on fast temporal kinetics and high spatial
resolution.
In vivo Fluorescence Imaging for Detecting
Aβ and Tau Pathologies
As most of the β-sheet binding chemical compounds engineered
for PET radiotracers possess their own fluorescence derived from
a polycyclic aromatic hydrocarbon backbone structure, these
small chemical compounds have ideal multimodalities for side-
by-side in vivo imaging comparison by both fluorescence and
PET techniques (Hawe et al., 2008). So far, studies focusing on
the beneficial usage of in vivo fluorescence approaches have been
published from only a few laboratories (Table 2). As pioneer
studies, SPs in APP transgenic mouse, which demonstrates
massive Aβ pathology, were first successfully visualized by the
hydrophilic chemical compound Thioflavin S or by anti-Aβ
antibody conjugated to fluorescein by two-photon microscopy
(Bacskai et al., 2001; Christie et al., 2001). Since these reagents
cannot penetrate BBB, the authors injected them directly into the
imaging area of the brain surface, demonstrating that the size and
morphology of SPs are rapidly cleared by immunization with Aβ
peptide during the course of a few days (Bacskai et al., 2001). The
relatively hydrophobic Congo-Red derivative Methoxy-X04 was
next developed and used to visualize Aβ pathology in brain of
APP transgenic mouse by intraperitoneal bolus administration
(Klunk et al., 2002). In addition, importantly, it was also verified
that Pittsburgh Compound-B (PiB) successfully visualized SPs
in mouse brain parenchyma by intravenous administration,
opening a new possibility for the simultaneous characterization
of a chemical tracer for both fluorescence and PET imaging
(Bacskai et al., 2003). The advantage of these compounds is their
ability to pass through BBB and therefore provide very important
information on the kinetics and tissue distribution of Aβ
pathology with great spatiotemporal resolution (∼µm for spatial
and∼sec for temporal). Although initial studies have suggested a
relatively stable appearance of existing SPs over several months,
more recent studies indicated that both SPs and cerebral amyloid
angiopathy (CAA), the cerebrovascular Aβ deposition in arterial
vessels, grow at a consistent rate (Robbins et al., 2006; Garcia-
Alloza et al., 2007; Hefendehl et al., 2011). It has also been
demonstrated that newly developed SPs grow rapidly for 24 h and
dynamically change their morphology, suggesting that steady-
state Aβ pathology undergoes flexible regulation by various
environmental factors in living animal. Similar approaches to
visualize tau pathology in Tau transgenic mouse model have
also been used. By direct application of Thioflavin S, NFTs
with neuronal loss in brain of rTg4510 tau transgenic mice
were first evaluated by multi-photon microscopy (Spires-Jones
et al., 2008). X-34, a Congo-Red derivative, and PBB3 were
next independently developed by different groups and used
for successful visualization of NFTs with great spatiotemporal
resolution by intravenous injection in living mouse models (de
Calignon et al., 2010; Maruyama et al., 2013). Although the
detailed in vivo time course of NFTs formation has not yet
been well-characterized, these studies promise the dual utility of
the compounds for both radiological and fluorescence in vivo
imaging applications. Importantly, both local abnormalities of
Aβ and Tau pathology can be detected bymulti-photon excitation
at a very early stage, indicating that the fluorescence approach
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TABLE 2 | Reference list for in vivo fluorescence imaging in living mouse model.
Mouse model Reagents and application for in vivo
visualization of SPs or NFTs
Fluorescence reporters for in vivo
visualization of AD pathophysiology
References
PDAPP (APP V717F) Thioflavin S, anti-Ab w/Fluorescein
(intracerebral injection)
Bacskai et al., 2001
Tg2576 (APPsw) Thioflavin S, anti-Ab (10D5) conjugated Cy3
(intracerebral injection)
Christie et al., 2001
PS-APP (PS1M146L vs. Tg2576) Methoxy-X04 (i.p.) Klunk et al., 2002
PDAPPTg2576PS-APP Thioflavin T, Thioflavin S, PiB (i.v.) Bacskai et al., 2003
Tg2576 Methoxy-X04 (i.p.) Robbins et al., 2006
PS1dEx9/APPsw curcumin (i.v.)
Methoxy-X04 (i.p.)
Garcia-Alloza et al., 2007
PS1L166P/APPsw Methoxy-X04 (i.p.) Hefendehl et al., 2011
3xTg-ADAPPdutch/iowaTg2576 – fluo-4 AM Takano et al., 2007
PS1dEx9/APPsw Methoxy-X04 (i.p.) YC3.60 camereon (AAV, intracerebral
injection)
Kuchibhotla et al., 2008
PS45(PS1G384A)/APP23(sw) Thioflavin S (intracerebral injection) Oregon green BAPTA Busche et al., 2008
PS1dEx9/APPsw Methoxy-X04 (i.p.) Oregon green BAPTA
SR-101 for astrocyte
Kuchibhotla et al., 2009
PS45/APP23 Thioflavin S (intracerebral injection) Fluo-8 AM Busche et al., 2012
PS1dEx9/APPsw Methoxy-X04 (i.p.) CaMKII 5′UTR-EGFP/Venus-3’UTR (AAV,
intracerebral injection)
Meyer-Luehmann et al., 2009
PS1dEx9/APPsw Methoxy-X04 (i.p.) Crossbreeding to Arc/dVenus mice Rudinskiy et al., 2012
Tg2576 Methoxy-X04 (i.p.) Crossbreeding to B6C3-YFP mice
Crossbreeding to Cx3CR1/GFP mice
Meyer-Luehmann et al., 2008
PDAPP Methoxy-X04 (i.p.) Crossbreeding to Cx3CR1 mice Koenigsknecht-Talboo et al., 2008
rTg4510 (Tau P301L) Thioflavin S (intracerebral injection) FLICA (intracerebral injection) Spires-Jones et al., 2008
rTg4510 (Tau P301L) Thiopflavin S (intracerebral injection) X-34 (i.v.) FLICA (intracerebral injection) de Calignon et al., 2010
PS19 (Tau P301S) PBB3 (i.p., i.v.) Maruyama et al., 2013
rTg4510 (Tau P301L) Thioflavin S (intracerebral injection) YC3.60 camereon (AAV, intracerebral
injection)
Kopeikina et al., 2013
rTg4510 (Tau P301L) Thioflavin S (intracerebral injection) YC3.60 camereon (AAV, intracerebral
injection)
Kuchibhotla et al., 2014
has a greater advantage for identifying beneficial molecular clues
linking early pathological change in AD model animals.
Utility of Fluorescence Biosensors of AD
Pathophysiology
Recently, unique functional fluorescence biosensors to monitor
biophysical properties were developed for dissecting the detailed
physiological status of animal brain. Since Green fluorescent
protein (GFP) was discovered from jellyfish Aequorea victoria
by Shimomura et al., many unique native fluorecent proteins
emitting diverse colors have been isolated from multiple marine
organisms (Shimomura et al., 1962). The improved fluorescent
proteins in terms of wavelength, brightness, photostability, and
less oligomeric property were successfully engineered by random
mutagenesis analysis, and the fluorescent protein color palette
has been extensively matured from blue to a near-infrared
spectrum (Giepmans et al., 2006). Engineered fluorescent
proteins with enhanced unique original properties (e.g., photo
activation/conversion, environment sensitivity, etc. . . . ) have
also been created during this process, opening a new window
to the utility of fluorescent proteins as molecular biosensors
generally termed “genetically encoded fluorescence indicators”
(GEFIs) to monitor a wide variety of biological parameters
including calcium, voltage, ATP, cAMP, glutamate, and kinase
activities (Knopfel, 2012;Miyawaki andNiino, 2015). In addition,
approaches to the use of virus-mediated gene delivery or
conventional animal genetics with specific promoter-dependent
regulation allow us to manipulate specific subpopulations of
neurons or glial cells, and GEFIs are certain to become a
powerful and broadly used tool for dissecting the molecular
pathophysiology of neurodegenerative disorders.
With the combination of fluorescence reporters and
biosensors, attempts have been made to illuminate the more
complicated AD-related pathophysiology by multi-photon
excitation techniques (Table 2). Abnormal dendritic curvature
and spine loss associated with SPs in brain of APP transgenic
mouse were first illuminated in living neurons expressing GFP by
either Adeno associated virus (AAV)-mediated manipulation or
by crossbreeding with fluorescence reporter mouse (Spires et al.,
2005). Using AAV-mediated overexpression of YC3.6 calcium
sensor proteins, Aβ pathology-related aberrant overloading
of neuronal calcium in the somatosensory cortex was then
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detected with great temporal resolution (Kuchibhotla et al.,
2008). Interestingly, local administration of Oregon-Green
BAPTA (OGB), a small-molecule calcium dye, also revealed
hyperactivity in neurons and disrupted synchronous calcium
oscillation in the astrocyte network associated with Aβ pathology
(Busche et al., 2008; Kuchibhotla et al., 2009). In addition,
inhibition of Ca2+/calmodulin-dependent protein phosphatase
2B (Calcineurin) attenuated the calcium dysregulation and
structural abnormality of neurites. These findings suggest
that dysfunction of calcium homeostasis is one of the key
environmental parameters related to amyloid pathology. In
addition to these observations, cross-breeding of APP transgenic
mice with Cx3CR1 mice, which specifically express GFP in
microglial cells, identified robust microglial activation associated
with Aβ pathology (Meyer-Luehmann et al., 2008). Importantly,
this immune response has been constantly observed during both
the development of SPs and anti-Aβ immunization, suggesting
that inflammation plays an essential role in the regulation
of the dynamics of Aβ pathology (Koenigsknecht-Talboo
et al., 2008). As an additional unique fluorescence reporter,
transgenic mouse expressing destabilized Venus under control
of immediate early gene Arc promoter was generated to identify
disrupted orchestrated neuronal network activity in an APP
transgenic mouse model (Rudinskiy et al., 2012). Taken together,
these studies strongly indicate the power of the fluorescence
system in combination with the current genetics approaches
to provide major insights into the AD pathophysiology. Using
the fluorescence indicator of caspase activation (FLICA), it
was also demonstrated that the majority of caspase-positive
neurons contain NFTs in brain of rTg4510 tau transgenic
mouse (Spires-Jones et al., 2008). Interestingly, infrequent NFTs-
negative neurons demonstrated rapid suppression of caspase
activity followed by NFTs formation within 1 day (de Calignon
et al., 2010). This indicates that NFTs formation potentially
has a neuroprotective role against caspase-mediated neuronal
apoptosis. The other surprising observation was that rTg4510
tau transgenic mouse demonstrated normal calcium dynamics
despite massive synaptic loss in both sensory and visual cortex,
suggesting that tau-related synaptic abnormality was induced
by a calcium-independent mechanism (Kopeikina et al., 2013;
Kuchibhotla et al., 2014). Dissection of the brain status of tau
transgenic mouse model by in vivo fluorescence imaging is still
at a developmental stage, and therefore additional studies with
fluorescence reporter can be expected to further expand the
future potential and contribution of the examination of the
tau-related pathophysiology of AD.
Limitations of Fluorescence Imaging
As we summarize in this section, fluorescence-based optic
imaging has become an attractive approach to simultaneously
monitor the interaction between target molecules and disease-
related pathophysiology with high spatiotemporal kinetics, and
to offer solid molecular-based insight for dissecting the in vivo
mechanism underlying the progression of the neurodegenerative
process in AD model animals. It also offers a relatively simple
and inexpensive system that can be relatively easy to install into
laboratory space, and potentially provide powerful biomedical
applications such as in vivo high-throughput drug screening.
However, considering future in vivo applications, there are still
many technical challenges and space that will require solutions.
First, the issue of optical diffusion tissue in vivo still strongly
restricts the visualization of fluorophore in only the surface area
even in mouse brain (reviewed in Svoboda and Yasuda, 2006).
Second, the potential invasiveness and toxicity caused by both
the surgery process and local genetic manipulation limit the
usage of these techniques in animals, although not in human
(reviewed in Hillman, 2007). Third, it is also important to note
that overexpression of fluorescent reporter proteins potentially
has undesirable photostability, toxicity, and mislocalization
(reviewed in Shaner et al., 2005). Based on an understanding of
these advantages and disadvantages, we will then consider how to
integrate each of the imagingmodalities in the future as described
in the last section.
PERSPECTIVES FOR FUTURE IMAGING
MULTIMODALITY
PET Imaging for Early Detection of AD
Pathology
The current successful establishment of Aβ and tau PET
radiotracers in combination with the available biomarkers
promises the availability of PET imaging for the clinical diagnosis
of AD. The next challenge for future PET neuroimaging is
the design of more advanced chemical probes that specifically
recognize the distinct conformational and/or modification status
of aggregates. In fact, it is known that PiB efficiently detects
SPs in AD brain but not in mouse brain, suggesting that a
modification process in different biological species can influence
the in vivo binding capability of the tracer (Klunk et al.,
2005). Recent studies suggest that not filamentous but soluble
oligomeric aggregates of Aβ and tau are toxic species during the
pathological course of AD (Cheng et al., 2013). In particular, tau
protein undergoes multiple post-translational modifications such
as phosphorylation, nitration, or truncation, which are predicted
to associate with the pathogenic mechanism(s) of AD (Marcus
and Schachter, 2011). Using in vitro aggregation assay, several
groups have successfully identified unique chemical compounds
that preferentially bind to intermediate aggregated species of Aβ
and tau (Wischik et al., 1996; Bolognesi et al., 2010; Smith et al.,
2010; Carrasco-Gallardo et al., 2012; Jameson and Dzyuba, 2013;
Teoh et al., 2015). More recently, pentameric formyl thiophene
acetic acid (pFTAA) was screened to successfully visualize the
conformation specific status of tau aggregates in living dorsal
root ganglion neurons isolated from tau transgenic mouse model
(Brelstaff et al., 2015). Therefore, some chemical compounds that
potentially have specific binding affinity to toxic oligomer or
modified species of Aβ and tau might be more suitable tracers for
the early detection of AD pathology. Various intermediates of tau
aggregates have been isolated during the pathological course of
NFTs formation, and it has been highly debated whether soluble
oligomeric aggregates of tau are toxic species (Makrides et al.,
2003; Maeda et al., 2006; Sahara et al., 2007; Peterson et al., 2008;
Lasagna-Reeves et al., 2010; Bader et al., 2011; Patterson et al.,
2011). It has also been hypothesized that the formation process
of intracellular tau inclusion potentially has a trophic role against
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tau toxicity (Spires-Jones et al., 2011; Cowan and Mudher, 2013).
In this regard, to segregate the early pathological tau species that
are toxic vs. those that are more neuroprotective would be a more
challenging, but also a more attractive investment for advanced
preclinical diagnosis. A fluorescence-based imaging approach
will have a great advantage in addressing this fundamental issue.
Current elegant studies have also demonstrated a cell-based
fluorescence system that can detect the very early stage of tau
aggregates isolated from juvenile tau transgenic mouse brain
by fluorescence resonance energy transfer (FRET), pointing out
its potential complementary application as a more physiological
drug screening system (Holmes et al., 2014). Taken together, it
is clearly important to expand multimodal imaging approaches
to characterize the basic capability of chemical compounds, and
this will eventually improve the screening efficiency and open
attractive directions for more sophisticated molecular diagnoses
with appropriate data interpretation.
Genetic Manipulation of Animal Models
To follow this multimodal approach, a key component would
be advancing technical innovation for genetic manipulation.
Many transgenic/knock-in mouse models overexpressing mutant
APP, PSs, and/or Tau have been established during the last two
decades, and a tremendous amount of fundamental knowledge
about the AD cascade has been acquired. However, these classical
genetic systems still have many limitations, as follows. First, it is
quite difficult to reproduce the spatiotemporal dynamics of the
AD pathological progression in these classical models because
transgene overexpression is controlled by specific promoter
activity. Second, it is still expensive and time-consuming to
generate mouse lines, and technical innovation to improve
productivity will be required. Third, rodent models may in fact
represent the ultimate limitation to the reproduction of the
human brain circumstances because of the species barrier. As an
advanced mouse model, a drug inducible Cre-loxP system, or a
Tet on/off system, has been incorporated into mouse genetics to
achieve more precise conditional control of transgene expression
(Santacruz et al., 2005). In recent studies, P301L mutant Tau
was strictly expressed in Layer II/III neurons in the entorhinal
cortex by neuropsin promoter in combination with a tetracycline
inducible system (de Calignon et al., 2012; Liu et al., 2012). An
interesting finding was that this region-specific expression of
tau causes progressive spreading of NFTs pathology along the
tri-synaptic entorhinal-hippocampus circuit in an anterograde
manner, suggesting the presence of toxic tau species that can be
transmitted via trans-synaptic communication. This prion-like
propagation theory is further supported by studies with in vivo
administration of fibrillar tau aggregates into mouse brains
resulting in the spread of tau pathology to synaptically connected
distant brain regions (Clavaguera et al., 2009, 2013; Lasagna-
Reeves et al., 2012; Iba et al., 2013). As an alternative approach,
the AAV system has become a widely used technique to achieve
spatiotemporal manipulation of transgene expression. In fact,
circuit-dependent pathological spreading of tau pathology was
also recently achieved by local administration of AAV-encoding
mutant tau into the entorhinal cortex of adult rodent (Siman
et al., 2013). Therefore, a very fascinating approach would be
to generate a tau mouse model genetically modified in the local
cell population of a specific neuronal circuit, and to trace the
in vivo spatiotemporal consequence of tau propagation in the
brain of the same individual living animal by fluorescence and
PET simultaneously, which would potentially facilitate further
understanding of non-cell autonomous toxic mechanisms shared
among various neurodegenerative disorders.
Very recently, an artificial nuclease-mediated gene edition
presented as the CRISPR/CAS9 system has rapidly expanded
its utility for the generation of animal models from insects
to a primate system (Sander and Joung, 2014). Using such
innovative tools, the establishment of genetic imaging reporter
animals is one of the attractive directions for future AD research.
Several studies have demonstrated that herpes simplex virus type
1 thymidine kinase (HSV1-TK)-mediated phosphorylation and
intracellular accumulation of nucleoside analogs such as 9-(4-
fluoro-3-hydroxymethylbutyl) guanine (FHBG) is a useful PET
reporter system for assessing gene expression, protein-protein
interactions, and enzymatic activity (Gambhir et al., 2000; Luker
et al., 2002; Massoud et al., 2010). Current advances in chemical
biology are also creating the potential availability of multiple new
technologies such as advanced affinity tag and light manipulation
for various in vivo imaging applications (Kramer et al., 2013).
Therefore, the combination of these genetic manipulations is
certain to contribute to the efficient development of advanced
animal model systems, and will allow us to conduct simultaneous
multimodal imaging comparisons to monitor the sequential
pathophysiology of AD progression.
CONCLUDING REMARKS
Multimodal neuroimaging may open an attractive direction for
future translational research, and allow us to simultaneously
monitor the actual behavior of target molecules of interest in
living subjects from a microscopic to a macroscopic view. Based
on the current progress of PET and the fluorescence system, there
are still a lot of areas and issues to be addressed, and integration of
these very different techniques will still present some challenging
hurdles. At this moment, all we need is to sincerely evaluate
both the advantages and disadvantages of individual imaging
systems, and to consider ways to complement these very different
techniques by seeking even small improvements in a step-by-
step manner. Eventually, this steady work and effort will result
in a breakthrough in the area of advanced biomedical research
including future diagnostics.
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